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The mapping of paediatric vaccination process in the United Kingdom (UK), as a 
precursor of a real-world study, is described. Methods: A targeted review of pub-
licly available information was conducted to gain comprehensive understanding 
of the paediatric vaccination process in the UK. A survey was designed eliciting 
the chronology of vaccination process prior to and on vaccination day, including 
estimates of active health care professional involvement. Face-to-face interviews 
with a nurse were conducted at three general practitioner surgeries routinely 
performing vaccinations. A subsequent follow-up call with each nurse was also 
arranged. Descriptive statistics were generated and preliminary cost calculations 
made. Results: Paediatric vaccination process can be broken down in 6 and 8 
clearly discernible steps prior to and on vaccination day, respectively. Activities 
prior to vaccination day include, among others, inventory, ordering, cold-chain 
management and are typically for multiple subjects. Mean time for those activities, 
recalculated per single vaccination visit, was 6.7 minutes, of which 61% dedicated 
to administrative duties. Activities on vaccination day include, among others, room 
preparation, consultation, vaccine administration. Estimated time per single visit 
totaled 25.4 minutes. Estimated total cost per single vaccine administration, with 
nurse salary cost from PSSRU, was £10.4. Costs may vary substantially depending 
on the level of “on-costs” to nurse’s gross salary. ConClusions: The detailed 
mapping of paediatric vaccination process in the UK identified clearly discernible 
tasks, time estimates, factors impacting variability of time outcomes, and early 
cost estimates. This forms the basis of a real-world T&M study aiming to generate 
robust time and cost outcomes.
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objeCtives: Guidelines for Health Technology Assessment (HTA) and Comparative 
Effectiveness Research (CER) largely focus on pharmaceuticals and only few explic-
itly consider other health care technologies. CER of medical devices (MD) faces some 
challenges that raise questions about how adequate current CER methods account 
for the specific features of MD and how well MD fit in the paradigm of drug HTA. Our 
aim was to identify challenges and gaps in methodology related to specific issues 
of MD. Our comprehensive framework for the evaluation of clinical effectiveness of 
MD includes recommendations for generation of primary data and analyzing and 
synthesizing data in systematic reviews of CER of MD. Methods: We performed a 
targeted literature review for CER methods and specific features of MD. An electronic 
database search was combined with systematic screening of tables of content of 
selected journals in the fields of epidemiology, HTA, statistics, and evidence-based 
medicine, which have a strong focus on methods. Additionally, we screened the 
reference lists of the most relevant papers. Results: More than 200 publications 
about the general evaluation of MD and about specific CER methods were included. 
The MD’s physical mechanism of action, the dynamic development and regulatory 
evidence requirements are the driving features that suggest the increased use of 
certain methods for the evidence generation, finding of information for HTA, data 
analysis and synthesis, and interpretation of results. Rather than following the para-
digms of drug evaluation, MD resemble more the notion of complex interventions. 
Our methodological framework is compatible with the EUnetHTA core model and 
integrates existing recommendations for other complex interventions. The con-
sideration of observational data, operator characteristics, active control trials, and 
decision-analytic modeling are of special importance, as well as the application of 
Bayesian methods. ConClusions: The assessment of the clinical effectiveness of 
MD does require specific, although not necessarily new methods.
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objeCtives: Poor adherence to anti-epileptic drugs has been shown to be the 
most important cause of poorly controlled epilepsy. Furthermore, it is emphasized 
that an increase in quality of life among patients with epilepsy could be reached 
by counseling and treatments aimed at increasing their self-efficacy and thus 
stimulate self-management. However, there is a need for evidence on the effec-
tiveness of such programs, especially within epilepsy care. Therefore, we have 
developed a multi-component intervention (MCI) which combines a self-manage-
ment/education program with e-Health interventions. Hence the overall objec-
tive of this study is to assess the (cost-) effectiveness of a MCI aiming to improve 
self-efficacy in people with epilepsy compared to care as usual. Methods: A 
randomized controlled trial in 2 parallel groups will be conducted to compare 
the MCI intervention with a waiting list control condition in epilepsy patients. 
One hundred eligible epilepsy patients will be recruited from the Kempenhaeghe 
epilepsy center and allocated to intervention or control group. Patients in the 
intervention group will receive an education program of six meetings including 
e-Health intervention and will be followed for 12 months. Patients in the control 
group will be followed for 6 months after which they will be offered to participate 
in the MCI. The study will consist of three parts: 1) a clinical effectiveness study, 
2) a cost-effectiveness study, and 3) a process evaluation. The primary outcome 
will be self-efficacy. Outcome assessments will be done using questionnaires at 
baseline and after 3, 6, 9, and 12 months. Results: N/A. ConClusions: This 
study will determine the (cost-) effectiveness of an MCI intervention to improve 
the self-efficacy of epilepsy in adult patients. The MCI is designed to stimulate 
self-management skills and awareness of epilepsy patients in combination with 
analyses reduce the probability of finding significant results due to chance while 
large numbers of outcome events reduce the overestimation of treatment effects. 
Our analysis finds that a statistically significant gain in OS is an important deci-
sion driver for even the most critical HTA agencies, although the treatment effect 
may still be questioned when the trial is unblinded early. HTA agencies appreciate 
to receive the latest available information (UK, Australia and Germany) and may 
reject the use of oncology drugs when there is too much uncertainty around OS 
estimates to justify the proposed price. It is generally useful to continue data col-
lection and follow-up patients should HTA agencies still request more reliable OS 
estimates for modeling purposes (UK and Australia) or long-term risk-benefit evalu-
ation (France). ConClusions: Payers are aware of the overestimation of effect size 
due to early trial termination and may reject drugs for high uncertainty around OS 
estimates. For adequate responses to requests for more reliable data, it is advised 
to continue data collection and follow-up patients.
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objeCtives: IBS is often a diagnosis of exclusion, with poor diagnosis coding in 
primary care and identification of eligible research participants challenging. We 
present the methodology of an on-going multi-centre, observational, retrospec-
tive research study, designed to overcome the challenges of IBS patient identifica-
tion. Methods: FARSITE, a software tool for identification of research participants 
developed by the Greater Manchester Comprehensive Local Research Network and 
North West eHealth, was used to screen anonymised primary care records for 
potentially eligible patients. Ethical approval reference 13/LO/0692. Search criteria: 
patients aged 18-60; combination READ code symptoms indicative of IBS and pre-
scription of IBS medications 01/01/2009–31/12/2011. GPs at 8 participating practices 
in Salford & Greater Manchester reviewed clinical records of the FARSITE-generated 
list of patients to apply full eligibility criteria for final patient selection. Inclusion 
criteria: medical diagnosis of IBS or meeting ROME III criteria; provision of consent. 
Exclusion Criteria: diagnosis excluding IBS; IBS symptoms secondary to other con-
dition; IBS medications only for non-GI symptoms. Results: FARSITE identified 
1089 (1.3%) patients, of which 297 (27.3%) were eligible. 97 patients consented to 
participation (79% female). Main reasons for non-eligibility were not meeting ROME 
III criteria or IBS excluded by medical opinion. Patients were most commonly coded 
as irritable colon (37%), difficulty defecating (21%), abdominal pain (18%), diarrhoea 
symptoms (14%). Four (4%) patients had a READ code specific for IBS. The median 
(IQR) time from 1st presentation with abdominal symptoms to study eligibility was 
3.98 (0.00-9.04) years. ConClusions: Identification of patients with IBS using READ 
codes is sub-optimal in primary care. A combination search of READ codes with 
symptom and prescription data via FARSITE has enabled potential participants to 
be identified with a reasonable screening failure rate. FARSITE is a valuable research 
tool aiding study feasibility by reducing the need for manual patient identification.
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objeCtives: Patient access to NBS has been greatly influenced by the 2006 
American College of Medical Genetics (ACMG) recommended expansion of NBS. 
ACMG relied largely on a stakeholder survey on 19 attributes of 84 rare conditions. 
The percentage of respondents agreeing to an attribute’s presence for a condition, 
along with its weight, determined attribute score. Sums of scores determined the 
entry point to an algorithm for final recommendations. This research examines 6 
attributes that appear to be associated with the same concept and asks whether 
these are really one (over-weighted) concept. Methods: The ACMG report pro-
vided attribute scores. Six questions addressed test efficiency (simplicity, high 
throughput, cost < $1/condition, multiple analytes/test run, other conditions 
identified/analyte, multiple conditions detected/test). We examined correlations 
between the 6 answers for a given condition across conditions and associations 
with recommendations. Results: After eliminating conditions with missing data, 
78 remained. Pairwise correlations between the 6 answers were high (mean= .85; 
range, .72-.96). Of those conditions (37) scoring at least 75% of the possible points 
on one question (“high throughput”), 79% were recommended as Core conditions 
to be screened and only 8% were Not Recommended. The mean total scores for the 
6 similar questions was 339 (500 possible). Of those (19) scoring 25% or fewer of the 
possible points for that one question, only 3% were Core, 72% Not Recommended 
(mean score:89). ConClusions: The high correlations support the idea that the 
6 similar questions were answered as if they were the same concept, weighting the 
common general attribute very highly. A more systematic approach, say MCDA, 
would likely have eliminated some of these questions with significant consequences 
for ACMG recommendations.
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objeCtives: Time and Motion (T&M) methodology allows quantifying time-
related outcomes for a health care delivery process by disaggregating the process 
in its constituent parts to measure task durations. The design of a T&M study 
requires early process mapping to define the time outcomes to be measured. 
